CBS issued an Amber Phase Advisory (2019-05-08) due to an unprecedented increase in SCIg utilization and imminent shortage of Cuvitru brand SCIg in Canada.

As a result, a working group consisting of neurologists, hematologists, immunologists and patient advocates issued short-term management recommendations to mitigate the risk to patients and their access to SCIg. Learn More.